CN102099493A - 用于预测对抗癌疗法的反应性的组合方法 - Google Patents

用于预测对抗癌疗法的反应性的组合方法 Download PDF

Info

Publication number
CN102099493A
CN102099493A CN2009801284436A CN200980128443A CN102099493A CN 102099493 A CN102099493 A CN 102099493A CN 2009801284436 A CN2009801284436 A CN 2009801284436A CN 200980128443 A CN200980128443 A CN 200980128443A CN 102099493 A CN102099493 A CN 102099493A
Authority
CN
China
Prior art keywords
timp
dna
top2a
her2
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801284436A
Other languages
English (en)
Chinese (zh)
Inventor
N·A·布伦纳
K·V·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Københavns Universitet
Original Assignee
Dako Denmark ApS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako Denmark ApS filed Critical Dako Denmark ApS
Publication of CN102099493A publication Critical patent/CN102099493A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2009801284436A 2008-05-20 2009-05-20 用于预测对抗癌疗法的反应性的组合方法 Pending CN102099493A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200800696 2008-05-20
DKPA200800696 2008-05-20
US5494408P 2008-05-21 2008-05-21
US61/054,944 2008-05-21
PCT/DK2009/050116 WO2009140973A1 (en) 2008-05-20 2009-05-20 A combined method for predicting the response to an anti-cancer therapy

Publications (1)

Publication Number Publication Date
CN102099493A true CN102099493A (zh) 2011-06-15

Family

ID=40010544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801284436A Pending CN102099493A (zh) 2008-05-20 2009-05-20 用于预测对抗癌疗法的反应性的组合方法

Country Status (7)

Country Link
US (1) US20110144047A1 (https=)
EP (1) EP2288729A1 (https=)
JP (1) JP2011520456A (https=)
CN (1) CN102099493A (https=)
AU (1) AU2009250169A1 (https=)
CA (1) CA2725171A1 (https=)
WO (1) WO2009140973A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105483255A (zh) * 2015-12-30 2016-04-13 广州安必平医药科技股份有限公司 Top2a基因检测探针及其制备方法和试剂盒
WO2017114011A1 (zh) * 2015-12-30 2017-07-06 广州安必平医药科技股份有限公司 Her-2基因和/或top2a基因检测探针及其制备方法和试剂盒

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002014A1 (en) * 2006-04-01 2008-12-17 Dako Denmark A/S Method for performing prognoses for high-risk breast cancer patients using top2a gene aberrations

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105483255A (zh) * 2015-12-30 2016-04-13 广州安必平医药科技股份有限公司 Top2a基因检测探针及其制备方法和试剂盒
WO2017114011A1 (zh) * 2015-12-30 2017-07-06 广州安必平医药科技股份有限公司 Her-2基因和/或top2a基因检测探针及其制备方法和试剂盒

Also Published As

Publication number Publication date
CA2725171A1 (en) 2009-11-26
US20110144047A1 (en) 2011-06-16
AU2009250169A1 (en) 2009-11-26
EP2288729A1 (en) 2011-03-02
JP2011520456A (ja) 2011-07-21
WO2009140973A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
Mitsuhashi et al. Prognostic significance of PRAME expression based on immunohistochemistry for diffuse large B-cell lymphoma patients treated with R-CHOP therapy
Ouyang et al. COP1, the negative regulator of ETV1, influences prognosis in triple-negative breast cancer
Le Quesne et al. A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material
Kanda et al. The expression of melanoma-associated antigen D2 both in surgically resected and serum samples serves as clinically relevant biomarker of gastric cancer progression
JP2014095726A (ja) ガンの診断、予測、および予後試験
JP7617634B2 (ja) 浸潤性乳癌のリスクを有する対象の治療の選択方法
US20140186837A1 (en) Methods For Diagnosing Cancer
Kim et al. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization
Liu et al. Jumonji domain-containing protein 1A promotes cell growth and progression via transactivation of c-Myc expression and predicts a poor prognosis in cervical cancer
Macedo et al. Multiple mutations in the Kras gene in colorectal cancer: review of the literature with two case reports
Wang et al. HPK1 positive expression associated with longer overall survival in patients with estrogen receptor-positive invasive ductal carcinoma‑not otherwise specified
Mi et al. Down-regulation of Barx2 predicts poor survival in colorectal cancer
da Silva et al. CCNA1 gene as a potential diagnostic marker in papillary thyroid cancer
WO2008132752A2 (en) Methods and kits for predicting cancer metastasis
US20140080782A1 (en) Methods of diagnosing and treating pancreatic cancer
Pegolo et al. One-step nucleic acid amplification (OSNA) for intraoperative evaluation of sentinel lymph node status in breast cancer: a comparative study between CK19 protein expression and CK19 mRNA level in primary tumors and lymph node metastasis
CN102099493A (zh) 用于预测对抗癌疗法的反应性的组合方法
Li et al. RETRACTED ARTICLE: Octamer transcription factor 1 mediates epithelial-mesenchymal transition in colorectal cancer
Liu et al. Prognostic value of insulin-like growth factor 2 mRNA-binding protein 3 and vascular endothelial growth factor-A in patients with primary non-small-cell lung cancer
US9702875B2 (en) Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
Mountzios et al. Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab
Lotfy et al. Biochemical study of E-cadherin and SATB1 in urothelial bladder carcinoma of Egyptian patients
EP3701049B1 (en) Diagnosis and/or prognosis of her2-dependent cancer using moesin as a biomarker
US20140120543A1 (en) Expression of isoform 202 of ercc1 for predicting response to cancer chemotherapy
Cohen et al. Expression of P53, P27 and KI‐67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based analysis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: RIGSHOSPITALET

Effective date: 20120420

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: IL B Laursen Patterson

Inventor after: Bruenner Nils Aage

Inventor after: Kristen Vang Nielsen

Inventor before: Bruenner Nils Aage

Inventor before: Kristen Vang Nielsen

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: BRUENNER NILS AAGE NIELSEN KRISTEN VANG TO: LAURSENERTSEN B. BRUENNER NILSAAGE NIELSEN KRISTEN VANG

TA01 Transfer of patent application right

Effective date of registration: 20120420

Address after: Danish Glostrup

Applicant after: Koebenhavns Uni

Co-applicant after: Riggs hospital

Address before: Danish Glostrup

Applicant before: Koebenhavns Uni

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110615